Development

发展

• 批准号: 8232200
• 负责人: Ramanuj Dasgupta
• 金额: $ 36.96万
• 依托单位: NEW YORK UNIVERSITY SCHOOL OF MEDICINE
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/8232200
• 关键词: Cancer Center Support Grant; Clinic; Clinical; Clinical Cancer Center; Clinical Research; Clinical Services; Collaborations; Communities; Complement; Core Facility; Development; Disease; Disease Management; Doctor of Philosophy; Environment; Epidemiologist; Epidemiology; Floor; Fostering; Funding; Genomics; Immunology; Immunotherapy; Institutes; Institution; Investigation; Investments; Japan; Laboratories; Laboratory Finding; Malignant Neoplasms; Mediation; Molecular; NCI Center for Cancer Research; Names; Pathology; Phase; Pilot Projects; Positioning Attribute; Prevention; Prevention program; Recommendation; Recruitment Activity; Research; Scientist; Site Visit; Small Interfering RNA; Source; Strategic Planning; Translating; Urogenital Cancer; Vaccines; base; clinical care; malignant breast neoplasm; melanoma; neoplasm resource; programs

Since the previous review, there have been 24 recruits to the Cancer Institute: seven translational, eight basic scientists, and nine clinical. Table 7.5.1 shows recruitments to date. While NYUCI institutional funds were used to support the expense of these recruits CCSG funds were used to fund pilot projects in the laboratories of many of these recruits, and to fund new cores without which these recruitments would not have been possible (e.g. Genomics Facility and siRNA core). As mentioned in Section 6.0 NYUCI recruitment took place in three phases during the last funding period. The first phase focused on key recruits with significant cancer focus that would complement the existing community. Thus the recruitment of Drs. Bhardwaj and O'Neill extended existing excellence in immunology to include immunotherapy as well as adding melanoma to our CCSG disease based programs that already included Genitourinary and Breast Cancer. The Chair of the Department of Pathology, David Roth, MD, PhD, and Co-Program Leader of the Immunology Program loaned the Cancer Institute space for the early recruitments of Drs. Bhardwaj, Dynlacht and O'Neill. This year, Drs. Bhardwaj and Dynlacht have since moved into the Cancer Research Center and Dr. O'Neill to the Vaccine Facility. The second phase focused on increasing depth in the clinical program with specific investments in recruits that would expand clinical services and research capabilities. The Clinical Cancer Center opened July 2004, and recruitment for disease based, programmatically aligned clinicians (e.g. Novik, Axelrod, Tiersten, Chandra, Skinner and others) prior to its opening provided for an environment of multi-disciplinary clinical research and care from its inception. Currently the NYUCI has 12 Disease Management Groups. Finally, with the opening of the Smilow Research Center May 2006, the three research floors of the Cancer Research Center opened and the newest recruits arrived on campus (Dasgupta, Yamasaki, Cho, Krogsgaard, Trombetta). Developmental Funds were earmarked to recruit a Deputy Director for Clinical Research to build the clinical research enterprise and foster collaborations across research entities to translate laboratory findings in the clinic, to recruit a molecular epidemiologist to bridge research within various programs, and build a collaborative and interactive Epidemiology and Prevention Program. These priorities were based upon the initiatives of the Strategic Plan and the recommendations of the EAB. In 2005, William Carroll, MD was named the Deputy Director for the Cancer Institute, responsible for the clinical research enterprise. We were, however, unsuccessful in recruiting a Molecular Epidemiologist, and in 2005, Dr. Roy Shore, the Associate Director for Epidemiology and Prevention took a position in Japan, and recruitment efforts to fill this position became our highest priority. In early 2006, a candidate was in final negotiations, yet decided to stay at his institution. The CI is actively recruiting for both positions and is in preliminary negotiations with one of the final candidates for the Associate Director position; our plan is to have this position filled by the Site Visit.

自之前的评论以来，癌症研究所已有24名新兵：七个翻译，八个 基础科学家和九个临床。表7.5.1显示了迄今为止的招聘。而Nyuci机构资金 用于支持这些新兵的费用CCSG资金用于资助试点项目 许多这些新兵的实验室，并为新的核心提供资金，而这些招募将不会 可能是可能的（例如基因组学设施和siRNA核心）。如第6.0节Nyuci招聘 在最后一个资金期间分为三个阶段。第一阶段的重点是关键新兵 重大的癌症重点将补充现有社区。因此，招募博士。 Bhardwaj和O'Neill扩展了现有的免疫学卓越，包括免疫疗法以及 将黑色素瘤添加到我们基于CCSG疾病的计划中，该计划已经包括泌尿生殖和乳房 癌症。病理学系主席David Roth，医学博士，博士和共同计划负责人 免疫学计划借给癌症研究所的空间，以提早招募DRS。 Bhardwaj，Dynlacht 和奥尼尔。今年，博士。此后，Bhardwaj和Dynlacht进入了癌症研究中心， 奥尼尔博士到疫苗设施。 第二阶段的重点是增加临床计划的深度，并在新兵方面进行特定的投资 这将扩大临床服务和研究能力。临床癌症中心于2004年7月开业， 以及基于疾病的，编程对准的临床医生的招聘（例如Novik，Axelrod，Tiersten， Chandra，Skinner等）在开放之前为多学科临床的环境提供了 从成立开始研究和护理。目前，Nyuci有12个疾病管理小组。最后，与 2006年5月，Smilow Research Center的开业是癌症研究中心的三个研究楼层 开业，最新的新兵到达校园（达斯古普塔，山崎，乔，克罗格斯加德，托兰贝塔）。 开发资金被指定为招募临床研究副主任，以建立 跨研究实体的临床研究企业和促进合作，以翻译实验室发现 该诊所，招募分子流行病学家来桥接各种计划中的研究，并建立一个 协作和互动流行病学与预防计划。这些优先事项是基于 战略计划的倡议和EAB的建议。 2005年，医学博士威廉·卡罗尔（William Carroll）是 负责临床研究企业的癌症研究所副主任。我们是 然而，在招募分子流行病学家方面未能成功，2005年，罗伊·肖尔博士（Roy Shore） 流行病学和预防总监在日本任职，并招募填补这一职位的努力 成为我们的最高优先事项。在2006年初，一名候选人进行了最后的谈判，但决定留在他的 机构。 CI正在积极招募这两个职位，并且正在与其中之一进行初步谈判 副主任职位的最终候选人；我们的计划是在现场访问中填补这个职位。